Nalts Has Low T! Asks Internet for a Diagnosis Based on His Brain MRI Images. Isn't There an App for That?
Nalts (aka "ADHD Boy", aka Kevin Nalty, Marketing Strategist, former Merck/Janssen-Cilag employee) posted a new YouTube video of his brain -- which includes a series of MRI scans. It seems he has "Low T" (low testosterone) and his doctor recommended the scan to see if his Low T is caused by a "pituitary issue." I hope he is OK and just growing old like the rest of us. As Nalts himself admits, he has no privacy when it comes to his health issues. I've blogged about his ADHD years ago (see "ADHD Boy").His brain scan video is his latest revelation about his health-related problems. In the video Nalts asks for some "wisdo...
Source: Pharma Marketing Blog - April 3, 2013 Category: Pharma Commentators Tags: Disease Mongering Nalts Kevin Nalty AbbVie Low T ADHD Disease awareness Androgel Source Type: blogs
Pharma Sets Record: Number of "Pay-for-Delay" Deals Hits 40 in 2012 Says FTC
According a new Federal Trade Commission (FTC) staff report, in Fiscal Year (FY) 2012, the number of "potentially anticompetitive patent dispute settlements" (aka, "Pay for Delay" deals) between branded and generic drug companies increased significantly compared with FY 2011, jumping from 28 to 40 (find the report here).Here's a plot of the data showing the trend over the past 9 years:The study also found that in nearly half of these settlements, branded firms may have used the promise that they would not develop or market an authorized generic (AG) as a payment to stall generic drug firms from marketing a competing produc...
Source: Pharma Marketing Blog - January 18, 2013 Category: Pharma Commentators Tags: Pay for Delay Lipitor Pfizer FTC Androgel Source Type: blogs
FTC: The Number Of Pay-To-Delay Deals Is Growing
As the US Supreme Court prepares to review the veracity of so-called pay-to-delay deals, in which a brand-name drugmaker agrees to pay a settlement to a generic rival in exchange for ending patent litigation and launching a copycat medicine at a future date, the US Federal Trade Commission has released its latest report that shows the number of these agreements has increased.
The court review is considered very significant, because its decision could determine the pace at which lower-cost generic drugs become available and, therefore, influence the cost of medicines for Americans. Drugmakers have struck dozens of these dea...
Source: Pharmalot - January 17, 2013 Category: Pharma Commentators Authors: Ed Silverman Tags: Uncategorized FTC Generic Drugs Merck Pay-To-Delay Supreme Court Source Type: blogs
The Supreme Court and "Pay for Delay:" The Potential Impact on Pharma
In early December of last year, the U.S. Supreme Court agreed to hear a case to decide whether agreements between brand-name pharmaceutical companies and generic makers to delay the entry of generic drugs to the market—so called “pay for delay” deals—violate antitrust laws. “In a typical case, a generic rival challenges the patent of a brand-name competitor, which then pays the rival a sum of money to drop its challenge,” reported Reuters.
Patents on drugs can last as long as 20 years and drug companies can sometimes extend the protection for their products by obtaining separate patents for a coating or ...
Source: Policy and Medicine - January 15, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
AbbVie's "Drive for Five" Campaign: Innovative, Derivative, and Conflictive?
In reviewing what pharmaceutical trade publications had to say about the industry in 2012, I came across MM&M's "All-Star" winners of the year. Sanofi, for example, was MM&M's "All-Star Company of the Year." What caught my attention, however, was the "All-Star Marketing Team of the Year: Androgel." That team is AbbVie - Abbott Laboratories's recently spun-off independent biopharmaceutical company - and its agencies, which include Digitas Health for consumer and AbelsonTaylor for professional ads.Androgel is a treatment for "low testosterone"; i.e., Primary hypogonadism and Hypogonadotropic hypogonadism. Or, as mark...
Source: Pharma Marketing Blog - January 4, 2013 Category: Pharma Commentators Tags: Abbott treatment guidelines AbbVie Low T Conflict of Interest testosterone Source Type: blogs
